ArticleESMO open2024

Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial.

C Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.